HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer
Abstract Breast cancer has constantly been the leading causes of death in women, and hormone receptor (HR) positive, HER2 negative is the majority subtype. Histone deacetylase (HDAC) inhibitors (HDACi) have shown clinical benefit in HR ( +) breast cancer patients. The Hippo pathway is an important c...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Clinical Epigenetics |
| Online Access: | https://doi.org/10.1186/s13148-025-01834-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|